Quick Answer
KalVista Pharmaceuticals, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $12.69 million for the year ending 2020.
- KalVista Pharmaceuticals, Inc. showed a decrease of -21.3% in Revenue From Contract With Customer Excluding Assessed Tax from 2019 to 2020.
- This data is from KalVista Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on July 7, 2022.
- XBRL data for this metric is available from 2017 to 2020 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: $96.0 thousand | Q4 2017: $1.13 million | Q1 2018: $2.33 million | Q2 2018: $4.84 million | Q3 2018: $3.72 million | Q4 2018: $5.59 million | Q1 2019: $3.89 million | Q2 2019: $2.93 million | Q3 2019: $3.37 million | Q4 2019: $3.92 million | Q1 2020: $1.58 million | Q2 2020: $3.82 million | Q3 2025: $1.43 million | Q3 2025: $13.69 million.
- Over the full 4 years of available data (2017 to 2020), KalVista Pharmaceuticals, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 743.8%.
- Historical annual values: Fiscal year 2020: $12.69 million | Fiscal year 2019: $16.13 million | Fiscal year 2018: $8.39 million | Fiscal year 2017: $1.50 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: